Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Zhou, Kali
    • Other Affiliation: University of California San Francisco; Department of Medicine; Division of Gastroenterology
  • Liang, Zhiwei
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Wang, Charles
    • Affiliation: School of Medicine, Department of Medicine
    • Other Affiliation: Brown University School of Medicine; Department of Medicine; Division of Gastroenterology
  • Hu, Fengyu
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Ning, Chuanyi
    • Affiliation: School of Medicine, Department of Medicine
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Lan, Yun
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Tang, Xiaoping
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Tucker, Joseph D.
    • Affiliation: School of Medicine, Department of Medicine
    • Other Affiliation: Guangzhou Eighth People's Hospital
  • Cai, Weiping
    • Other Affiliation: Guangzhou Eighth People's Hospital
Abstract
  • The advent of direct-acting agents (DAAs) has improved treatment of HCV in HIV co-infection, but may be limited by primary drug resistance. This study reports the prevalence of natural polymorphisms conferring resistance to NS3/4A protease inhibitors and NS5B polymerase inhibitors in treatment-naïve HIV/HCV co-infected individuals in China.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • PloS One
Journal volume
  • 11
Journal issue
  • 6
Page start
  • e0157438
Language
  • English
ISSN
  • 1932-6203

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details PubMedCentral-PMC4920402.pdf 2016 Public Download